Description
CJC-1295 + Ipamorelin
Synthetic dual peptide complex for in vitro research on synergistic GHRH and GHS-R1a receptor signaling pathways
Overview & Mechanism of Action (In Vitro)
CJC-1295 + Ipamorelin is a laboratory-engineered dual-peptide blend combining two complementary research compounds in an equimolar ratio: the tetra-substituted growth hormone-releasing hormone analog (CJC-1295 no DAC / Mod GRF 1-29) and the highly selective pentapeptide secretagogue (Ipamorelin). In molecular endocrinology, it serves to model dual-receptor agonism on isolated somatotrope cell lines:
- Synergistic Activation of Distinct Signaling Cascades: Simultaneous stimulation of the GHRH-R receptor (via the Gs-protein cAMP/PKA pathway driven by CJC-1295) and the GHS-R1a receptor (via the Gq-protein phospholipase C and intracellular calcium ion Ca2+ mobilization pathway driven by Ipamorelin).
- High Binding Selectivity of Ipamorelin: Specific interaction with the ghrelin receptor without exhibiting in vitro cross-reactivity toward ACTH, cortisol, prolactin, FSH, or LH pathways.
- Extended Enzymatic Resistance of CJC-1295: Four D- and modified amino acid substitutions protect the peptide backbone from rapid cleavage by dipeptidyl peptidase-4 (DPP-4) in experimental culture media.
The combination of both compounds in laboratory models elicits a multiplicative transcriptional and secretagogue response compared to the isolated application of either peptide alone.
Technical & Chemical Specifications
- Classification: Research Peptide Complex / Dual GHRH-R & GHS-R1a Agonist
- Blend Composition: CJC-1295 no DAC (Mod GRF 1-29) + Ipamorelin
- Form: Sterile lyophilized white powder (cake)
- Component Identification: Verified via Mass Spectrometry (MS) and analytical HPLC
- Recommended Reconstitution Solvent: Sterile bacteriostatic water or phosphate-buffered saline (PBS)
- Storage Conditions: Store long-term at -20 °C in a dry, dark environment. Following reconstitution, keep refrigerated at 2–8 °C and utilize within standard experimental protocol timelines.
Scientific References & Literature
- Raun, K., et al. Ipamorelin, the first selective growth hormone secretagogue: In vitro characterization and receptor binding profiles. European Journal of Endocrinology, 1998.
- Jette, L., et al. Human growth hormone-releasing factor analogs: Chemical optimization and prolonged bioactivity in cellular systems. Endocrinology, 2005.
- Bowers, C. Y. Synergistic interaction between GHRH and growth hormone-releasing peptides in primary pituitary cultures. Journal of Pediatric Endocrinology & Metabolism, 1993.
- Sackmann-Sala, L., et al. Mechanisms of dual receptor activation on transcription and intracellular signaling in model somatotropes. Growth Hormone & IGF Research, 2009.
Legal Disclaimer & Terms of Purchase
This product is classified and supplied strictly for laboratory, scientific, and in vitro research purposes only (Research Use Only – RUO). This compound is not a drug, medicine, dietary supplement, cosmetic product, or substance intended for human or veterinary consumption, direct administration, injection, or diagnostic procedures.
By placing an order, the purchaser explicitly confirms that they are at least 18 years of age, possess the requisite professional qualifications and laboratory equipment to safely handle research materials, and are fully conversant with all relevant safety protocols for managing research substances. The seller assumes no liability for any use contrary to these terms.




